Zoetis Inc. $ZTS Shares Purchased by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 193.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,393 shares of the company’s stock after purchasing an additional 4,873 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Zoetis were worth $930,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after purchasing an additional 419,777 shares during the last quarter. Nordea Investment Management AB raised its holdings in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Zoetis by 14.6% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after purchasing an additional 550,859 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Zoetis by 13.3% in the third quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after acquiring an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP lifted its position in shares of Zoetis by 25.3% in the third quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after acquiring an additional 730,300 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $120.81 on Thursday. The firm has a market capitalization of $50.82 billion, a PE ratio of 20.07, a P/E/G ratio of 1.85 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a 50-day moving average of $121.98 and a two-hundred day moving average of $126.70. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ZTS shares. Citigroup started coverage on Zoetis in a research report on Wednesday. They issued a “buy” rating and a $145.00 price objective on the stock. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $152.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.